The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%.

Original languageEnglish (US)
JournalInternational Journal of Impotence Research
Volume20
Issue numberSUPPL. 3
DOIs
StatePublished - Dec 2008

Fingerprint

Prostatic Hyperplasia
Prostate-Specific Antigen
Antigens
Lower Urinary Tract Symptoms
Serum
Prostate
Prostatic Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

@article{709e960c3ff045b0b5bddc3b632751fd,
title = "The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia",
abstract = "Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50{\%}.",
author = "Claus Roehrborn",
year = "2008",
month = "12",
doi = "10.1038/ijir.2008.53",
language = "English (US)",
volume = "20",
journal = "International Journal of Impotence Research",
issn = "0955-9930",
publisher = "Nature Publishing Group",
number = "SUPPL. 3",

}

TY - JOUR

T1 - The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia

AU - Roehrborn, Claus

PY - 2008/12

Y1 - 2008/12

N2 - Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%.

AB - Several analyses have demonstrated a clinically useful relationship between serum prostate specific antigen (PSA) and prostate volume in men with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Both prostate volume and serum PSA predict certain aspects of the natural history of LUTS and BPH, and men with higher PSA and larger glands in general have a higher rate of progression measured by various parameters. Serum PSA also predicts the response to certain types of medical therapy in men with LUTS and BPH and is thus useful in the evaluation and management of these patients. Lastly, serum PSA does not loose its usefulness as a cancer marker for prostate cancer even if certain medications reduce serum PSA values predictably by 50%.

UR - http://www.scopus.com/inward/record.url?scp=55849115219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55849115219&partnerID=8YFLogxK

U2 - 10.1038/ijir.2008.53

DO - 10.1038/ijir.2008.53

M3 - Article

C2 - 19002120

AN - SCOPUS:55849115219

VL - 20

JO - International Journal of Impotence Research

JF - International Journal of Impotence Research

SN - 0955-9930

IS - SUPPL. 3

ER -